Carbohydrate-based Adjuvant Development

Carbohydrate-based Adjuvant Development

Adjuvants enhance the body's immune response by triggering and regulating innate and adaptive immunity. CD BioGlyco has committed to developing carbohydrate adjuvants for many years and we are pleased to share our knowledge and experience to advance your adjuvant research.


Compared with traditional vaccines, subunit vaccines based on homologous antigens have the advantages of precise targeting and improved safety. The vaccines require adjuvants to enhance the immunogenicity of the antigen for optimal vaccine efficacy. However, the mechanisms by which adjuvants enhance immune responses are poorly understood in humans. This phenomenon has hindered the development of the vaccine field. Aluminum salts have been approved for use in human vaccines as the only adjuvant for over 70 years. Therefore, there is an urgent need to develop novel, potent, and less toxic adjuvants to enhance the immunogenicity of subunit vaccines.

Carbohydrate-based Vaccine Adjuvant Development

Carbohydrates are the most widely distributed biological macromolecules in nature and have the advantages of good biocompatibility, strong tolerance, and high safety. In addition, they also play a key role in immune regulation. Currently, many carbohydrates derived from plants, bacteria, and yeast have been evaluated as potential candidate adjuvants. For example, Deltin adjuvant is effective in animal models of human immunodeficiency virus (HIV) vaccines, avian influenza (H5N1) vaccines, Japanese encephalitis vaccines, and African equine disease vaccines. Now, the adjuvant is in the clinical research stage for human hepatitis B and antiviral vaccines.

Our Services

Based on the advantages of carbohydrates and their application potential in the field of adjuvant, CD BioGlyco provides high-quality carbohydrate-based adjuvant development services to meet customers' needs. Our adjuvant development services include lipopolysaccharide, bacterial outer membrane vesicles (OMVs), trehalose glycolipid, galactosylceramide, peptidoglycan, chitin/chitosan, inulin, mannans, alginate, saponin, α-glucan, lentinan, β-glucans, Deltin, muramyldipeptide, cord factor, zwitterionic polysaccharides, and novel plant polysaccharides.

CD BioGlyco provides our customers with high-quality, cost-effective, and hassle-free adjuvant development services. If you are interested in our services, please contact us directly. We are looking forward to being your indispensable assistant in adjuvant development.


  1. Petrovsky, N.; Cooper, P.D. Carbohydrate-based immune adjuvants. Expert review of vaccines. 2011, 10(4):523-537.
  2. Pifferi, C.; et al. Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action. Nature Reviews Chemistry. 2021, 5(3): 97-216.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.